Is Stem Cell a Curer or an Obstruction?

Darmayanti, Siska; Triana, Rina; Chouw, Angliana; Dewi, Nurrani Mustika

doi:10.21705/mcbs.v1i1.12

Cited by 9 publications

(11 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A case report on a 65-year-old woman by Liang et al showed no adverse event and patient improvement 4 days post-injection of 5.0 × 10 7 cells/administration UC-MSCs. However, in the long-term evaluation, a comparison between doses and routes of administration is needed to provide the best outcome for the patient [ 21 , 68 ]. It is also important that the MSCs and MSC-derived secretome are produced in a good manufacturing practices (GMP) compliance facility to ensure the quality of the cell and eliminate the batch-to-batch variation [ 34 ].…”

Section: Msc-based Clinical Trials For Covid-19mentioning

confidence: 99%

Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19

Chouw

Milanda

Sartika³

et al. 2021

Regen. Eng. Transl. Med.

Self Cite

View full text Add to dashboard Cite

The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19. Lay Summary The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.

show abstract

Section: Msc-based Clinical Trials For Covid-19mentioning

confidence: 99%

Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19

Chouw

Milanda

Sartika³

et al. 2021

Regen. Eng. Transl. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 Telah banyak uji klinis yang menggunakan sel punca untuk mengobati penyakit lainnya, seperti gangguan sistem imun, gangguan neurologis, gangguan jantung, serta gangguan persendian. [2][3][4] Darah tali pusat mengandung sel punca hematopoietik (hematopoietic stem cell/HSC) dan jenis sel punca lain, seperti very small embryonic-like stem cell (VSEL). 5 Sel punca merupakan sel yang mampu memperbanyak dirinya dan berdiferensiasi menjadi sel lain yang ada di dalam tubuh.…”

Section: Pendahuluanunclassified

Pengaruh Usia Ibu Hamil terhadap Jumlah Sel Punca Hematopoietik dan Very Small Embryonic-like Stem Cell pada Darah Tali Pusat

Chouw¹,

Putera²,

Sartika³

et al. 2019

ijcp

Self Cite

View full text Add to dashboard Cite

AbstrakDarah tali pusat telah banyak digunakan dalam terapi regeneratif. Hal ini disebabkan darah tali pusat mengandung sel punca, yaitu sel punca hematopoietik dan very small embryonic-like stem cell. Keberhasilan terapi regeneratif menggunakan darah tali pusat membutuhkan dosis yang disesuaikan dengan berat badan dan cara pemberian sel punca. Oleh karena itu, dibutuhkan informasi yang dapat memengaruhi jumlah sel punca yang ada pada darah tali pusat. Usia ibu pada saat kehamilan diperkirakan memiliki pengaruh terhadap jumlah sel punca. Penelitian ini dilakukan dengan pendekatan studi potong lintang. Penelitian dilakukan di Laboratorium Prodia StemCell Indonesia pada bulan Desember 2017. Sebanyak 22 sampel yang digunakan dalam penelitian ini merupakan darah tali pusat yang telah disimpan sebelumnya selama lebih dari dua tahun. Deteksi jumlah sel hematopoietik dan very small embryoniclike stem cell dilakukan dengan menggunakan metode flowcytometry. Deteksi sel punca hematopoietik dilakukan dengan menggunakan molekul penanda permukaan CD34+ dan CD45+, sedangkan deteksi very small embryonic-like stem cell dilakukan dengan menggunakan molekul penanda permukaan CD45-, CD34+, dan CD184(CXCR4)+. Pada kelompok usia ibu di atas 30 tahun, rata-rata jumlah sel hematopoietik adalah 63,71±58.419x10 3 sel/mL dan rata-rata jumlah very small embryonic-like stem cell adalah 7,83±7.060 x10 3 sel/mL. Uji beda menunjukkan semakin tua usia ibu pada saat kehamilan, jumlah sel punca semakin meningkat, namun tidak ada perbedaan yang signifikan (r=0,0510; p<0,005). Hal ini menunjukkan bahwa usia ibu tidak memengaruhi konsentrasi sel darah tali pusat. Kata kunci: Darah tali pusat, sel hematopoietik, sel punca, very small embryonic-like stem cell AbstractUmbilical cord blood (UCB) has been used in regenerative medicine due to the stem cell content in the blood. Hematopoietic stem cell and very small embryonic-like stem cell are found in UCB sample. Dosage and route of administration of stem cell need to be determined for the success of regenerative therapy. Therefore, information that can affect the stem cell number is needed. This study used crosssectional approach, and was conducted at Prodia StemCell Laboratory in December 2017. Twenty-two UCB samples collected from Prodia StemCell Laboratory which had been stored for more than 2 years were thawed to detect the number of stem cell. Flowcytometry method was used to detect the number of hematopoietic stem cell and very small embryonic-like stem cell in UCB sample. Hematopoietic stem cell was detected using antibody CD34+ and CD45+ while very small embryonic-like stem cell was detected using CD45-, CD34+, and CD184(CXCR4)+. The mean cell number of hematopoietic stem cell and very small embryonic-like stem cell in maternal age above 30 years old group were 63.71 ±58.419x10 3 cell/mL and 7.83±7.060 x10 3 cell/mL, respectively. There was no significant difference in maternal age group during pregnancy (r=0.0510; p<0.005). In conclusion, the number of cells in umbilical cord blood due to the ...

show abstract

“…(8) MSCs are pluripotent stem cells that can be found in a variety of places throughout the body, including bone marrow, fat, vasculature, liver, and umbilical cord blood. (9)(10)(11) Three processes are involved in the formation of bone tissue: osteogenesis, modeling, and remodeling.…”

Section: Introductionmentioning

confidence: 99%

3D Biosilica Scaffolds from Melophlus sarasinorum and Xestospongia testudinaria Indonesian Sponges are Biocompatible for Cell Growth and Differentiation of Human Wharton’s Jelly Mesenchymal Stem Cell in Bone Tissue Engineering

et al. 2022

View full text Add to dashboard Cite

BACKGROUND: Biosilica derived from Indonesian marine sponge Melophlus sarasinorum and Xestospongia testudinaria is one of the biomaterials that can be developed together with synthetic polymer as a composite. Poly E-caprolactone (PCL) used as a composite role as an osteoconductive material together with biosilica and also tailored the slow rate of degradation in the body. This study aimed to create a biocompatible biosilica-based scaffold and supports osteogenic differentiation of human Wharton's Jelly mesenchymal stem cell (hWJ-MSCs).METHODS: Biosilica was extracted from M. sarasinorum and X. testudinaria with the acid digestion method. Scaffold was prepared using the salt leaching method. The composite scaffolds were made from seven different biosilica extract and PCL. All of the scaffolds were tested for the cell morphology, Fourier-transform infrared spectroscopy (FTIR), immunocytochemistry, and cytotoxicity.RESULTS: Composite scaffolds of 50% M. sarasinorum and X. testudinaria increased the cell viability and supported the cell growth within 14 days, whereas the osteogenic differentiation can be seen by the presence of collagen type 1 in day 12 based on immunocytochemistry result.CONCLUSION: The biosilica scaffolds from PCL+50% M. sarasinorum and PCL+50% X. testudinaria were promising 3D scaffolds for potential application in bone tissue engineering. In conclusion, this study shows evidence for the osteogenic differentiation of hWJ-MSC, which might be developed for bone tissue engineering.KEYWORDS: sponge, biosilica, scaffold, osteogenesis, stem cell

show abstract

Is Stem Cell a Curer or an Obstruction?

Cited by 9 publications

References 61 publications

Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19

Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19

Pengaruh Usia Ibu Hamil terhadap Jumlah Sel Punca Hematopoietik dan Very Small Embryonic-like Stem Cell pada Darah Tali Pusat

3D Biosilica Scaffolds from Melophlus sarasinorum and Xestospongia testudinaria Indonesian Sponges are Biocompatible for Cell Growth and Differentiation of Human Wharton’s Jelly Mesenchymal Stem Cell in Bone Tissue Engineering

Contact Info

Product

Resources

About